MAPKAPK2 and atherosclerosis: In this study, we have identified two new orally active small-molecule MK2 inhibitors, TBX-1 and TBX-2, and tested their effect on advanced atherosclerosis progression of established plaques in high fat-fed Ldlr-/- mice.